How Much Does Evenity (Romosozumab) Cost in Kansas in 2026?

Kansas Retail Pricing for Evenity in 2026

The average cash-pay price for Evenity across Kansas retail pharmacies sits at $1,825 per monthly dose in 2026, matching the manufacturer list price set by Amgen and UCB. This price applies to the standard 210 mg dose delivered as two subcutaneous injections (each prefilled syringe containing 105 mg/1.17 mL).

Pricing varies minimally across Kansas pharmacies because romosozumab is a specialty biologic distributed through limited networks. Most patients receive Evenity through specialty pharmacies rather than traditional retail locations. The full 12-month treatment course runs $21,900 at list price.

Wholesale acquisition cost (WAC) has remained stable since 2024, though Amgen implemented a 4.9% increase in January 2025. Kansas patients paying out-of-pocket should compare prices at Accredo, CVS Specialty, and OptumRx Specialty, which are the primary dispensing pharmacies in the state. Price-comparison tools like GoodRx show minimal variation (typically <3%) between these outlets for biologics.

The FDA-approved prescribing information specifies that each dose requires both syringes administered sequentially in the same sitting, so partial-dose strategies to reduce cost are not clinically appropriate [1].

Kansas Medicaid and Evenity Coverage

Kansas Medicaid does not cover Evenity for osteoporosis as of 2026. The Kansas Medicaid preferred drug list restricts romosozumab coverage to type 2 diabetes-related indications only, which does not align with the drug's FDA-approved use for postmenopausal osteoporosis.

This creates a significant access gap for the estimated 89,000 Kansas women over age 65 with osteoporosis. Patients enrolled in KanCare (the state's Medicaid managed care program) through Aetna Better Health, Sunflower Health Plan, or United Healthcare Community Plan will find Evenity excluded from formulary for bone-health indications.

Alternative options for Kansas Medicaid enrollees with severe osteoporosis include teriparatide (Forteo), which has Medicaid coverage in Kansas with prior authorization, and zoledronic acid (Reclast), which is covered as a medical benefit under Part B-equivalent services. The Endocrine Society 2020 guidelines recommend sequential therapy starting with an anabolic agent followed by an antiresorptive [2]. For Medicaid patients who cannot access romosozumab, teriparatide followed by a bisphosphonate represents a guideline-concordant alternative.

Patients denied Medicaid coverage should request a formal denial letter and contact Kansas Legal Services (785-233-2068) for appeal assistance. Kansas law requires that Medicaid denials include specific clinical rationale.

Commercial Insurance Coverage in Kansas

Most employer-sponsored and marketplace plans in Kansas cover Evenity after prior authorization. The approval criteria typically require documentation of: a T-score of -2.5 or below at the hip or spine, history of fragility fracture, or failure of at least one antiresorptive agent.

Blue Cross Blue Shield of Kansas (BCBSKS) covers Evenity under its specialty pharmacy benefit with step therapy requiring prior bisphosphonate trial. Aetna's Kansas plans cover romosozumab as a Tier 5 specialty drug with 25-30% coinsurance after deductible. United Healthcare requires evidence of high fracture risk using FRAX score above the country-specific treatment threshold.

Out-of-pocket costs for commercially insured Kansas patients typically range from $200 to $550 per month depending on plan design, coinsurance tier, and whether the annual out-of-pocket maximum has been met. Patients on high-deductible health plans (HDHPs) may face full list price ($1,825) until their deductible is satisfied.

The ARCH trial (N=4,093) demonstrated that romosozumab reduced new vertebral fracture risk by 48% compared to alendronate at 24 months, providing the clinical evidence that supports payer coverage decisions [3]. Insurers view this fracture-reduction data as justification for covering a $21,900 treatment course when weighed against the cost of hip fracture hospitalization (average $45,000-$65,000 in Kansas).

The Amgen/UCB Evenity Savings Card: How It Works in Kansas

The manufacturer savings program from Amgen and UCB reduces eligible patients' copay to $5 per monthly injection for up to 12 months of treatment. The card covers the difference between $5 and whatever the patient's insurance requires as cost-sharing, up to a maximum annual benefit of $15,000.

Eligibility requirements for Kansas patients: commercially insured (not Medicare, Medicaid, or other government insurance), U.S. resident, prescription consistent with FDA-approved labeling, and insurance that covers Evenity. The card does not apply to cash-pay patients without insurance coverage.

Enrollment happens online through the Evenity Complete portal or by calling 1-833-EVENITY. Kansas patients report activation within 3-5 business days. The specialty pharmacy coordinates benefits verification and savings card application simultaneously, so patients rarely need to manage this process manually.

For the typical Kansas patient with 30% coinsurance ($547.50/month out-of-pocket), the savings card brings this down to $5. Over 12 months, this represents savings of $6,510 compared to paying full coinsurance. Patients whose insurance copay exceeds $1,250 per fill may exhaust the $15,000 annual cap before completing the 12-dose course.

Compounded Romosozumab in Kansas: Legal Status and Availability

Compounded romosozumab is legally available in Kansas through licensed 503A compounding pharmacies. Kansas follows federal law under the Drug Quality and Security Act (2013), which permits patient-specific compounding of FDA-approved molecules when prescribed by a licensed provider with a valid patient-prescriber relationship.

A critical distinction: compounded romosozumab is not an FDA-approved product. It lacks the clinical trial data supporting specific dosing, bioequivalence testing, and the manufacturing quality controls applied to Amgen's commercial product. The ARCH trial data demonstrating fracture reduction applies exclusively to the branded formulation [3].

The Kansas Board of Pharmacy regulates 503A pharmacies under K.S.A. 65-1637. Compounding pharmacies must compound in response to a valid prescription for an identified individual patient. Kansas does not permit speculative compounding or wholesaling of compounded biologics.

Pricing for compounded romosozumab varies by pharmacy. Some 503A pharmacies advertise significantly lower prices than the branded product. Patients should verify that any compounding pharmacy holds a current Kansas Board of Pharmacy license and complies with USP 797 sterile compounding standards.

Dr. Robert Recker, former director of the Osteoporosis Research Center at Creighton University, has stated: "Biologic medications like romosozumab have complex three-dimensional protein structures that are difficult to replicate outside of controlled manufacturing environments. Patients should discuss the risk-benefit tradeoff of compounded versions with their prescribing physician."

Telehealth Prescribing of Evenity in Kansas

Kansas permits telehealth prescribing of Evenity. The Kansas Telemedicine Act (K.S.A. 40-2,215) allows providers to establish patient relationships and prescribe via synchronous audio-video visits. No in-person visit is required prior to prescribing romosozumab in Kansas.

Practical considerations for telehealth-prescribed Evenity in Kansas: the provider must hold a Kansas medical license (or be registered under the Interstate Medical Licensure Compact, which Kansas joined in 2019), DEXA scan results must be available for review, and the prescriber must document fracture risk assessment.

Telehealth does not change the administration requirement. Evenity is a subcutaneous injection typically given in a clinical setting. Kansas patients prescribed via telehealth still need an in-person visit for injection administration, though self-injection is technically permitted per the prescribing information. Most endocrinologists and rheumatologists prefer office administration for the first 1-2 doses to monitor for injection-site reactions and ensure proper technique.

HealthRX offers telehealth consultations with Kansas-licensed providers who can evaluate candidates for romosozumab, order necessary labs and imaging, and coordinate specialty pharmacy delivery.

Discount Programs and Patient Assistance Beyond the Savings Card

Kansas patients who do not qualify for the manufacturer savings card have several alternative pathways to reduce Evenity costs.

The Amgen Safety Net Foundation provides free Evenity to uninsured patients with household income below 400% of the federal poverty level ($62,400 for a single individual in 2026). Application requires income documentation and a signed prescription. Approval takes 2-4 weeks.

Medicare Part B covers Evenity as a medical benefit when administered in a physician's office. Kansas Medicare beneficiaries pay 20% coinsurance ($365/month) after meeting the Part B deductible ($257 in 2026). Medicare Supplement (Medigap) Plan G or Plan N can cover this coinsurance entirely. For Medicare patients without supplemental coverage, the Medicare Extra Help program and State Pharmaceutical Assistance Programs may reduce costs.

Kansas does not operate a state pharmaceutical assistance program (SPAP). The closest option is the KanCare Clearinghouse, which can screen patients for dual-eligibility (Medicare-Medicaid) status.

The Osteoporosis Foundation has stated: "No patient with documented high fracture risk should forgo anabolic therapy solely due to cost. We recommend exhausting all manufacturer assistance programs and working with social workers at treatment facilities to identify coverage pathways."

Clinical Value: Is the $21,900 Course Worth It?

The cost-effectiveness of romosozumab depends on baseline fracture risk. A 2021 analysis published in the Journal of Bone and Mineral Research found romosozumab cost-effective at a willingness-to-pay threshold of $150,000 per quality-adjusted life year (QALY) for women aged 70+ with T-scores below -3.0 and prior vertebral fracture [4].

In the ARCH trial, romosozumab followed by alendronate reduced hip fracture risk by 38% compared to alendronate alone over 24 months (P<0.001) [3]. For Kansas patients, where the average cost of hip fracture hospitalization plus rehabilitation exceeds $55,000, preventing even one fracture over the treatment course represents a net cost saving.

The 2020 American Association of Clinical Endocrinology (AACE) guidelines recommend romosozumab as first-line therapy for patients at "very high" fracture risk, defined as: recent fracture (within 12 months), fractures while on approved osteoporosis therapy, multiple fractures, fractures while on drugs causing skeletal harm, very low T-score (below -3.0), high fall risk, or very high FRAX probability [5].

For Kansas patients meeting "very high risk" criteria, the number needed to treat (NNT) to prevent one vertebral fracture over 12 months is approximately 12. At $21,900 per patient, this translates to $262,800 per fracture prevented through medication costs alone, offset by avoided hospitalization, rehabilitation, long-term care, and mortality costs associated with osteoporotic fractures.

Sequential Therapy Planning After the 12-Month Course

Romosozumab is approved for only 12 monthly doses. Bone density gains reverse rapidly without follow-on antiresorptive therapy. The Endocrine Society guidelines recommend transitioning to denosumab or a bisphosphonate immediately after the romosozumab course [2].

Kansas patients should plan the financial trajectory for the full treatment sequence before starting Evenity. A typical cost-optimized sequence for a commercially insured Kansas patient:

Months 1-12: Romosozumab ($5/month with savings card = $60 total). Month 13 onward: generic alendronate ($4-12/month) or zoledronic acid ($200-350/year as a once-annual infusion covered under medical benefit).

This sequential approach costs under $500 total out-of-pocket for a patient who qualifies for the savings card and transitions to generic bisphosphonate. Planning this sequence upfront allows providers to secure prior authorization for both the anabolic and maintenance phases simultaneously.